Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
120
resultados
Última actualización
01/05/2026 [07:36:00]
Resultados 100 a 120 de 120
Resumen de: US20260061128A1
Techniques disclosed herein relate to safe correction boluses. In some embodiments, the techniques involve obtaining a plurality of sensor glucose readings for a patient. The techniques may further involve determining, based on the plurality of sensor glucose readings that the patient has consumed a meal. The techniques may further involve in response to determining the patient has consumed the meal, reducing a hypoglycemia threshold from a first value to a second value lower than the first value. The techniques may further involve determining a correction bolus dosage based on the reduced hypoglycemia threshold.
Resumen de: AU2025279723A1
Described herein are fixed doses and dosing regimens for long-acting insulin receptor agonists suitable for once-weekly dosing, such as weekly basal insulin-Fc (BIF). ec e c
Resumen de: US20260061129A1
Exemplary embodiments may enable a user to schedule medicament bolus deliveries, such as insulin boluses, for future dates and times. The exemplary embodiments may provide the ability to delay a scheduled medicament bolus delivery by short periods of time. The user may reschedule a scheduled medicament bolus delivery by entering a new date and/or time for the medicament bolus delivery. Still further, a user may cancel a scheduled medicament bolus delivery. In addition, exemplary embodiments may enable multiple medicament bolus deliveries to be viewed and managed.
Resumen de: US20260066125A1
Provided are devices and systems for determining a blood glucose level for a subject, the device comprising a processor and a memory in communication with the processor, the device comprising: a receiving unit for obtaining a voice sample from the subject; an extraction unit for extracting at least one voice biomarker feature value from the voice sample for at least one predetermined voice biomarker feature; a determining unit for determining the blood glucose level for the subject based on the at least one voice biomarker feature value and a blood glucose level prediction model; and an output unit for outputting the blood glucose level or an output based on the blood glucose level for the subject.
Resumen de: US20260061122A1
A device in accordance with an embodiment of the present technology includes a port through which the device receives and dispenses infusion liquid (e.g., insulin solution) and a container that holds the infusion liquid. The device also includes a hub at a flowpath extending between the port and the container. The hub defines a first passage and a second passage in parallel with one another. The device further includes a conditioner and a check valve at the first and second passages, respectively. The conditioner conditions liquid moving between the container and the port by passing the liquid through an adsorbent filter and a mechanical filter. The check valve causes liquid moving between the port and the container to move preferentially via the first passage when flowing in one direction and to move preferentially via the second passage when flowing in an opposite direction.
Resumen de: WO2026049829A1
A computer implemented method matching an individual's continuous metabolite monitoring traces with another individual's continuous metabolite monitoring traces begins by identifying a concentration level of a metabolite for a subject. Dividing metabolic states into ranges of concentration levels allows for transforming a concentration level into a symbol from a set of symbols, wherein the symbol represents a category of concentration levels. The method identifies one or more strings of symbols, wherein each string of symbols represents a series of one or more symbols corresponding to a series of transformed concentration levels represented by the symbols. A computer is programmed to determine a lexical distance between a first string from the one or more strings of symbols and a second string, wherein the lexical distance corresponds to a degree of similarity between the first string and the second string. The computer provides a search result for a search query based on the determined lexical distance.
Resumen de: WO2026047019A1
The present invention relates to amino acid solutions for parenteral administration comprising amino acids and a pharmaceutically acceptable form of copper, as well as to containers comprising, in separate chambers, said amino acid solutions and a lipid emulsion for parenteral administration and/or a glucose solution for parenteral administration.
Resumen de: WO2026047021A1
The present invention relates to lipid emulsions for parenteral administration comprising an oil phase and a pharmaceutically acceptable form of selenium, as well as to containers comprising, in separate chambers, said emulsions and an amino acid solution for parenteral administration and/or a glucose solution for parenteral administration.
Resumen de: WO2026045148A1
The present disclosure provides a method for producing views related to data on glucose and ketone bodies and a related system. The method comprises receiving analyte data from an analyte sensor; determining, on the basis of the received analyte data, analyte concentration data comprising glucose concentration data and ketone body concentration data; and displaying, on the basis of the analyte concentration data, on a display unit a plurality of views comprising a first view, wherein the first view comprises a graphical display generated on the basis of the analyte concentration data over a time period, the graphical display comprises a region representing the distribution of a plurality of data points, and the position of each data point is determined by the glucose concentration and the ketone body concentration at the same time. The present disclosure enables an observer to more conveniently analyze energy metabolism and is friendlier to the observer.
Resumen de: WO2026049295A1
A blood glucose management system is disclosed, comprising a user terminal configured to capture an image of food, a processor, and an information providing device configured to provide the processor with blood glucose time-series information of a user prior to ingestion of the food. The processor is configured to execute a step of generating blood glucose trend prediction information of the user after ingestion of the food, based on data related to the food captured by the user terminal and the blood glucose time-series information. The user terminal is configured to display the blood glucose trend prediction information.
Resumen de: US20260066121A1
An embodiment may provide a blood glucose measurement method using a learning model, the method including obtaining a biosignal, generating biometric data from the biosignal, training a learning model with training biometric data, so as to output a blood glucose value, obtaining a blood glucose value corresponding to the biometric data from the biometric data via the learning model when training is completed, and providing, to a user, the blood glucose value corresponding to the biometric data.
Resumen de: WO2026045149A1
Provided in the present disclosure are an analyte concentration data-based processing device and a related method. The processing device comprises an acquisition module and a processing module. The acquisition module is configured to receive first analyte data related to a glucose concentration and second analyte data related to a ketone body concentration obtained by continuously monitoring at least two analytes of a target subject using an analyte sensor. The processing module is configured to acquire, on the basis of the first analyte data and the second analyte data, analyte concentration data comprising glucose concentration data and ketone body concentration data, acquire, on the basis of the analyte concentration data within a time period, at least one feature set, and determine, on the basis of the at least one feature set, target information at least comprising energy information. The energy information is the relationship between estimated energy intake and energy expenditure of the target subject, where the energy intake is the energy derived from ingested carbohydrates, and the energy expenditure is the energy that is consumed. Therefore, the convenience of evaluating the relationship between carbohydrate intake and consumption can be improved.
Resumen de: WO2026047017A1
The present invention relates to glucose solutions for parenteral administration comprising glucose and a pharmaceutically acceptable form of iron, as well as to containers comprising, in separate chambers, said glucose solutions and a lipid emulsion for parenteral administration and/or an amino acid solution for parenteral administration.
Resumen de: CN121038691A
Methods and systems for monitoring blood glucose levels of a subject are described, the method comprising the steps of: continuously acquiring electrocardiogram parameters of the subject, the electrocardiogram parameters comprising heart rate, heart rate variability, QT interval, and Tp/Rp ratio; inputting the acquired electrocardiogram parameters into a learning algorithm for processing the parameters; and outputting a continuously updated output value representative of the blood glucose level of the subject.
Resumen de: EP4702921A1
The present application relates to a method and apparatus for analyzing a blood glucose concentration, a device, a storage medium, and a computer program product. The method comprises: acquiring intensity sets corresponding to a plurality of photoplethysmography pulse wave sets for a target object in a target time period, the intensity set comprising an average alternating-current intensity and an average direct-current intensity; performing curve fitting on the plurality of intensity sets to obtain a fitting coefficient and a fitting bias; comparing the fitting bias with a bias range corresponding to the target object, and when it is determined that the fitting bias is not within the bias range, adjusting the fitting bias to obtain an adjusted fitting bias; and performing, on the basis of the adjusted fitting bias, curve fitting on the plurality of intensity sets to obtain an adjusted fitting coefficient, and taking the adjusted fitting coefficient as the blood glucose concentration of the target object in the target time period. By adopting the method, the accuracy of blood glucose concentration analysis can be improved.
Resumen de: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Resumen de: MX2025015762A
According to an aspect, there is provided a computer-implemented method (200) of determining a concentration of glucose in a subject's blood, the method comprising acquiring (202) first measurement data indicative of a response resulting from an electromagnetic (EM) signal interacting with the subject's blood in a body part of the subject, the EM signal having been emitted from a device in contact with the body part of the subject; acquiring (204) second measurement data indicative of a pressure applied to the body part of the subject by the device; and using (206) a predictive model to infer a concentration of glucose in the subject's blood from the first measurement data and the second measurement data, the predictive model having been trained to infer a concentration of glucose in the subject's blood from the first measurement data and the second measurement data.
Resumen de: US2019313905A1
0001 The present disclosure relates to techniques for receiving glucose data from a continuous glucose sensor and controlling the use and redistribution of that data so it is used in an intended manner. In one aspect, a system includes a plurality of continuous glucose monitor (CGM) devices; a plurality of display devices to receive data from the CGM devices classified into a plurality of classifications based on data type; a cloud server architecture to receive the data from the display devices on an intermittent basis, in which the data routed to a particular server of the plurality of servers is determined by the data type, and in which the intermittent basis varies depending upon data type; a plurality of remote monitor display devices; and an analysis and report engine.
Resumen de: MX2025012556A
Novel compositions of N-desmethyl ruboxistaurin L-lactate. The use of compositions of N-desmethyl ruboxistaurin L-lactate to modulate GSK-3 signaling is disclosed, as is the use of compositions of N-desmethyl ruboxistaurin L-lactate to inhibit protein kinase C. Methods are also disclosed of using compositions of N-desmethyl ruboxistaurin L-lactate in the treatment of subjects having a neurological disease and/or psychiatric disorder, including Alzheimer's disease, bipolar disorder, depression, schizophrenia, Parkinson's disease, or neuroinflammation, as well as methods of using compositions of N-desmethyl ruboxistaurin L-lactate in treating conditions associated with diabetes mellitus or its complications, or ischemia, inflammation, pulmonary hypertension, congestive heart failure, cardiovascular disease, dermatological disease, or cancer. In addition, compositions of N-desmethyl ruboxistaurin L-lactate administered in combination with lithium or other treatments for bipolar disorder are also disclosed.
Nº publicación: MX2025015111A 02/03/2026
Solicitante:
SUNSHINE LAKE PHARMA CO LTD [CN]
Resumen de: MX2025015111A
A GLP-1-Fc-FGF21 double-target fusion protein composition and the use thereof. The composition comprises a GLP-1-Fc-FGF21 fusion protein and a buffer solution. In the composition, by means of adding the buffer solution, the generation of visible particles can be effectively controlled, and the stability of the GLP-1-Fc-FGF21 fusion protein is improved, so that the shelf life of a product can be prolonged. The composition can be used for treating and/or preventing metabolic diseases, such as diabetes, hyperlipidemia, obesity and diseases related to fatty liver.
BOPI
Sede Electrónica
